A few weeks ago there was some discussion on there was some discussion on her re the durability of Rux for PV. Below is a answer to that from Dr V in a interview with Targeted Oncolgy in Nov 2022
In polycythemia vera, ruxolitinib is valuable as a second-line choice when things don't go well with hydroxyurea. Patients then have much higher white blood cell counts, may have a big spleen, and of course, require phlebotomy. In that setting, it has been proven in 2 randomized studies that ruxolitinib provides a significant clinical benefit in normalizing blood cell count, improving quality of life, and decreasing spleen in those that have a big spleen. It appears after many years of follow-up that this is very durable, and possibly decreases the risk of early death from the complications of uncontrolled polycythemia vera. We use it often in the second-line setting, and it is a number 1 choice in PV.